Turn Therapeutics (NASDAQ:TTRX) Upgraded at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other research analysts have also commented on the company. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Wall Street Zen raised Turn Therapeutics to a “hold” rating in a report on Saturday, July 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Price Performance

Turn Therapeutics stock opened at $9.62 on Monday. The company’s 50 day simple moving average is $6.70 and its 200-day simple moving average is $4.81. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The company has a market capitalization of $286.58 million and a price-to-earnings ratio of -50.63.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. As a group, equities research analysts expect that Turn Therapeutics will post -0.09 earnings per share for the current year.

Hedge Funds Weigh In On Turn Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Hodges Capital Management Inc. bought a new stake in shares of Turn Therapeutics during the fourth quarter valued at approximately $39,000. LPL Financial LLC acquired a new stake in Turn Therapeutics during the fourth quarter valued at approximately $51,000. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics during the 4th quarter valued at $59,000. Composition Wealth LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter valued at $63,000. Finally, Geode Capital Management LLC purchased a new position in shares of Turn Therapeutics in the fourth quarter worth approximately $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.